Akebia Therapeutics (AKBA) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Akebia Therapeutics (AKBA) over the past year, gaining 75.5% versus a loss of 70.4%. Over five years, SLGL leads with a -22.8% price change compared with -69.4% for AKBA. Akebia Therapeutics is the larger company by market cap ($237.1 million vs $229.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | SLGL |
|---|---|---|
| Share price | $0.8555 | $70.03 |
| Market cap | $237.06M | $229.28M |
| 1-day change | -2.05% | -2.66% |
| YTD return | -45.75% | +70.73% |
| 1-year return | -70.39% | +75.52% |
| 5-year return | -69.35% | -22.85% |
| EPS (TTM) | $-0.12 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $97.97 |
| 52-week low | $0.814 | $28.81 |
| Distance from 52-week high | -73.27% | -28.52% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +358.21% | +117.76% |
| Average volume | 6.13M | 55.30K |
| Shares outstanding | 277.11M | 3.27M |
| Employees | 194 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed AKBA by 145.9 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
AKBA vs SLGL FAQ
Which is bigger, Akebia Therapeutics or Sol-Gel Technologies?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $237.06M compared with $229.28M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, AKBA or SLGL?
SLGL returned +75.52% over the past 12 months, compared with -70.39% for AKBA (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.